• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1277934 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type5 [3 d7 l* ]( K) S
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
7 u$ ^$ m" A& k# f3 Y, {9 c* X+ Author Affiliations
, T9 @) c% E3 }% p! M+ `4 v/ }0 o& ^2 A# l8 b8 [( j, E
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan , o, m8 F6 b# B1 W; s8 e
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
  S1 N. m  e: ?5 c8 s; u+ R. n3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan   O2 c# O- |0 Y% `' D1 O3 p1 K
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 7 h& m( r( w' D# `+ y0 ]9 e
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
8 o/ N% G2 R# ^1 M3 x6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan - {0 F; s' g' k. q2 u1 x8 f
7Kinki University School of Medicine, Osaka 589-8511, Japan , ?& O( s  K, H* |5 J( ~8 _
8Izumi Municipal Hospital, Osaka 594-0071, Japan
/ Q3 G8 p& {- K0 A5 V9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 2 H% B* l% C  M1 @
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ' P% w+ u8 c2 n( f+ n+ I, S
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
- M* Q* G; z$ [" b
- u3 d; E% R0 \- t: L1 s
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type , x( X6 O9 g* A& d% g, U) y

: A. n4 [1 i7 Y' d  a' ?! wAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato / i' L1 [0 ~" \1 Q9 N+ l
, ]8 ]% i/ Y5 i( b9 R
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  9 ^: Y0 I. g; ^5 D

: g7 l8 v6 o0 L  ^Published online on: Thursday, December 1, 2011 4 D5 l' N; b1 E& m
6 s% C" t2 m: C" ~5 B
Doi: 10.3892/ol.2011.507 2 ^4 ?/ H& _7 X3 t
3 f3 U" p0 {  A
Pages: 405-410
) g. \7 M4 S4 w) k9 B. n9 K" k2 r# m1 ^0 K
Abstract:
6 {" P3 q4 m  k4 ^) e( qS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
7 K: l0 [- D5 ~2 J ' v* X; b4 |! b% [& _& O+ S
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population% b3 E0 e# b  [0 V
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 3 _; w) Q( m; a
+ Author Affiliations* \1 `6 U$ r" K+ K, Z. M1 i& a: I
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
, r( j6 t0 \" ]! n  w6 B2Department of Thoracic Surgery, Kyoto University, Kyoto 6 T* o0 v0 E% \/ B* Y3 e
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
8 ?* A/ H. [" n0 t3 k&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp + n3 g! `1 j( I$ K) E) Z
Received September 3, 2010. # u! C; C" r/ k6 b4 E1 k  j
Revision received November 11, 2010.
9 A) P& u+ _3 R9 a. P) {Accepted November 17, 2010. & L! M8 O3 L2 \! _
Abstract
8 ?4 N' x, Q( [# v) BBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. - i8 z/ J3 [1 ?3 O4 R
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
0 C5 w' }( D5 z* J' }* FResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
! g: C; M; C* ~Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
9 U8 b3 h3 e9 B" v* e) D- U
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
: ]% C% f% {! l6 ?5 i# \今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
: N4 O1 T0 N, D/ ^( |; O$ @0 u
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
. M) p5 ]* A  r9 @- T6 Hhttp://clinicaltrials.gov/ct2/show/NCT01523587; h5 x% Y; P8 H" U7 e0 v( A
2 S  P7 |# N( a6 B# x
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC$ s+ p2 i$ ~- w; p: J2 k! w+ o* d- K
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
2 m* i3 T4 O- f* }( g
# w+ |9 Y0 O0 y2 ]8 Z. p" ]* u从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
* i& G3 Q; h& d, ^至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
" Q0 e& S$ H" ]( ~. U: b* E5 f
没有副作用是第一追求,效果显著是第二追求。
( O3 I6 x* X3 \8 e) H9 |% h; X. P不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表